Ad
related to: frequent incomplete yawning in children causes and remedies
Search results
Results From The WOW.Com Content Network
Drowsiness, yawning, disinclination for work, lack of social participation, mood changes, apathy, sleep disturbances, other fatigue-related symptoms The sopite syndrome ( / s oʊ ˈ p aɪ t / ; from Latin sopire 'to put to sleep') [ 1 ] is a neurological disorder that relates symptoms of fatigue , drowsiness , and mood changes to prolonged ...
328 participants were asked to watch a three-minute video of people yawning and to keep track of how many times they yawned. Of the 328 participants, 222 contagiously yawned.
Puberphonia (also known as mutational falsetto, functional falsetto, incomplete mutation, adolescent falsetto, or pubescent falsetto) is a functional voice disorder that is characterized by the habitual use of a high-pitched voice after puberty, hence why many refer to the disorder as resulting in a 'falsetto' voice. [1]
Yawning often feels involuntary—it’s triggered by the same part of the brain as sneezing, Sullivan says. But the difference is, a yawn can be controlled from “the top down” if you think ...
Yawning. We all do it and yet there's no set explanation on why we do it. And just as mysterious is that the act of yawning seems to be contagious. A new study looking at that issue has found that ...
Research data strongly suggest that neither contagious nor story-induced yawning is reliable in children below the age of six years. [8] Nervousness, which often indicates the perception of an impending need for action, has also been suggested as a cause. Anecdotal evidence suggests that yawning helps increase a person's alertness.
Hypernasal speech is a disorder that causes abnormal resonance in a human's voice due to increased airflow through the nose during speech. It is caused by an open nasal cavity resulting from an incomplete closure of the soft palate and/or velopharyngeal sphincter ( velopharyngeal insufficiency ). [ 1 ]
Dextromethorphan/quinidine is a combination of these two generic drugs, and is the first FDA-approved drug for the treatment of PBA, approved on October 29, 2010. [ 50 ] In the pivotal multicenter study that led to its approval, the "Objectives...[were] to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 ...